|
1
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in children and young adults with
B-Cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park JH, Rivière I, Gonen M, Wang X,
Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et
al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic
leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar
|
|
3
|
Cappell KM, Sherry RM, Yang JC, Goff SL,
Vanasse DA, McIntyre L, Rosenberg SA and Kochenderfer JN: Long-term
follow-up of Anti-CD19 chimeric antigen receptor T-Cell therapy. J
Clin Oncol. 38:3805–3815. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ,
Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large
B-cell lymphoma and indolent B-cell malignancies can be effectively
treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar :
|
|
5
|
Raje N, Berdeja J, Lin Y, Siegel D,
Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A,
et al: Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or
refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019.
View Article : Google Scholar
|
|
6
|
Sterner RC and Sterner RM: CAR-T cell
therapy: Current limitations and potential strategies. Blood Cancer
J. 11:692021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kochenderfer JN, Dudley ME, Feldman SA,
Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes
MS, Sherry RM, et al: B-cell depletion and remissions of malignancy
along with cytokine-associated toxicity in a clinical trial of
anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood.
119:2709–2720. 2012. View Article : Google Scholar
|
|
8
|
Long AH, Haso WM, Shern JF, Wanhainen KM,
Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara
VR, et al: 4-1BB costimulation ameliorates T cell exhaustion
induced by tonic signaling of chimeric antigen receptors. Nat Med.
21:581–590. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lynn RC, Weber EW, Sotillo E, Gennert D,
Xu P, Good Z, Anbunathan H, Lattin J, Jones R, Tieu V, et al: c-Jun
overexpression in CAR T cells induces exhaustion resistance.
Nature. 576:293–300. 2019. View Article : Google Scholar
|
|
10
|
Roybal KT, Williams JZ, Morsut L, Rupp LJ,
Kolinko I, Choe JH, Walker WJ, McNally KA and Lim WA: Engineering T
cells with customized therapeutic response programs using synthetic
notch receptors. Cell. 167:419–432.e416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taube R, Zhu Q, Xu C, Diaz-Griffero F, Sui
J, Kamau E, Dwyer M, Aird D and Marasco WA: Lentivirus display:
Stable expression of human antibodies on the surface of human cells
and virus particles. PLoS One. 3:e31812008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lindsten K, Uhlíková T, Konvalinka J,
Masucci MG and Dantuma NP: Cell-based fluorescence assay for human
immunodeficiency virus type 1 protease activity. Antimicrob Agents
Chemother. 45:2616–2622. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weissman AM, Hou D, Orloff DG, Modi WS,
Seuanez H, O'Brien SJ and Klausner RD: Molecular cloning and
chromosomal localization of the human T-cell receptor zeta chain:
Distinction from the molecular CD3 complex. Proc Natl Acad Sci USA.
85:9709–9713. 1988. View Article : Google Scholar
|
|
14
|
Conchello JA and Lichtman JW: Optical
sectioning microscopy. Nat Methods. 2:920–931. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanda Y: Investigation of the freely
available easy-to-use software 'EZR' for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar
|
|
16
|
Navia MA and McKeever BM: A role for the
aspartyl protease from the human immunodeficiency virus type 1
(HIV-1) in the orchestration of virus assembly. Ann NY Acad Sci.
616:73–85. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wilkins MR, Gasteiger E, Bairoch A,
Sanchez JC, Williams KL, Appel RD and Hochstrasser DF: Protein
identification and analysis tools in the ExPASy server. Methods Mol
Biol. 112:531–552. 1999.PubMed/NCBI
|
|
18
|
Liu Z, Chen O, Wall JB, Zheng M, Zhou Y,
Wang L, Vaseghi HR, Qian L and Liu J: Systematic comparison of 2A
peptides for cloning multi-genes in a polycistronic vector. Sci
Rep. 7:21932017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carter P, Presta L, Gorman CM, Ridgway JB,
Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM:
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Proc Natl Acad Sci USA. 89:4285–4289. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho JH, Collins JJ and Wong WW: Universal
chimeric antigen receptors for multiplexed and logical control of T
cell responses. Cell. 173:1426–1438.e1411. 2018. View Article : Google Scholar :
|
|
21
|
Choe JH, Watchmaker PB, Simic MS, Gilbert
RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al:
SynNotch-CAR T cells overcome challenges of specificity,
heterogeneity, and persistence in treating glioblastoma. Sci Transl
Med. 13:eabe73782021. View Article : Google Scholar :
|
|
22
|
Fedorov VD, Themeli M and Sadelain M:
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors
(iCARs) divert off-target immunotherapy responses. Sci Transl Med.
5:215ra1722013. View Article : Google Scholar
|
|
23
|
Mager PP: The active site of HIV-1
protease. Med Res Rev. 21:348–353. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boice M, Salloum D, Mourcin F, Sanghvi V,
Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G,
et al: Loss of the HVEM tumor suppressor in lymphoma and
restoration by modified CAR-T cells. Cell. 167:405–418.e413. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lamers CH, Klaver Y, Gratama JW, Sleijfer
S and Debets R: Treatment of metastatic renal cell carcinoma (mRCC)
with CAIX CAR-engineered T-cells-a completed study overview.
Biochem Soc Trans. 44:951–959. 2016. View Article : Google Scholar
|
|
26
|
Morgan RA, Yang JC, Kitano M, Dudley ME,
Laurencot CM and Rosenberg SA: Case report of a serious adverse
event following the administration of T cells transduced with a
chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
2010. View Article : Google Scholar : PubMed/NCBI
|
